Global Diabetes Associated Ophthalmic Treatment Market Size (By Type: Drugs, and Devices; By Application: Diabetic Retinopathy, Diabetic Macular Edema, Diabetic Associated Macular Degeneration, Cataracts, Glaucoma, Eye Allergy and Infection, Uveitis, and Others; By End-User: Hospitals, Ambulatory Surgical Centers, Ophthalmic Clinics, and Others) - Global Industry Analysis, Market Size, Opportunities and Forecast, 2021 - 2028
The global diabetes associated ophthalmic treatment market accounted for US$ 26.14 billion in 2020 and is likely to increase at a CAGR of 6.9% from 2021 to 2028.
Diabetes associated ophthalmic treatment is nothing but eye-related disorders that are caused by diabetes. Diabetic retinopathy, for example, is an eye illness that affects persons who have diabetes. Diabetic retinopathy occurs when the blood vessels in the retina are damages by the high blood sugar levels. These blood vessels have the ability to grow in size and leak. They can also close, obstructing the flow of blood and abnormal new blood vessels can grow on the retina. All of these changes may cause your eyesight to become hazy. Nearly one-third of diabetics develop retinopathy, or damage to the blood vessels in the retina, at some point. The lining at the back of your eye is that. The most common type of retinopathy is non-proliferative retinopathy, which does not usually cause vision loss. The most effective treatments to prevent diabetic retinopathy are to control diabetes and manage early symptoms.
The increasing number of diabetes patients across the world is the primary factor boosting the growth of global diabetes associated ophthalmic treatment market. In 2021, diabetes affected around 537 million persons aged 20 to 79. By 2030, the aggregate number of diabetes is predicted to reach 643 Mn, and it will arrive at 783 Mn by 2045. In addition, 541 million adults are at increased risk of developing type 2 diabetes in 2021. Three out of every four adults with diabetes live in a low- or middle-income country. Companies perform a variety of retinal surgery procedures, including vitreous cleansing for diabetics and retinal surgery procedures using cutting-edge technology and top-of-the-line dissecting microscopes.
Diabetes harms the eyes when blood glucose, also known as blood sugar, is too high. Individuals are unlikely to experience vision loss as a result of excessive blood glucose in the short term. For a few days or weeks after changing their diabetes treatment plan or medicines, people may have cloudy vision. High blood sugar levels can cause fluid imbalances or swelling in the tissues that aid focus, resulting in blurred vision. This type of blurred vision is only temporary, and it will go away as your blood glucose level returns to normal.
Growth in the elderly population is also a key aspect that fuels diabetes associated ophthalmic treatment market. Diabetic eye disease affects the older population disproportionately. The old population is expected to reach 1.5 billion in 2050, according to the World Population Ageing Report. However, the dearth of skilled ophthalmologists in emerging economies is limiting the market growth. Furthermore, growing awareness regarding ophthalmic treatments as well as the benefits of early adoption of diabetic retinopathy is likely to create various growth opportunities for the market in the coming years.
Type, application, end-user, and regions are the four segments of global diabetes associated ophthalmic treatment industry. The type segment is further bifurcated into drugs and devices. Based on application, the segmentation includes diabetic retinopathy, diabetic macular edema, diabetic associated macular degeneration, cataracts, glaucoma, eye allergy and infection, uveitis, and others. Furthermore, the end-user segment is categorized into hospitals, ambulatory surgical centers, ophthalmic clinics, and others.
Global Diabetes Associated Ophthalmic Treatment Market Regional Competition
North America, Europe, Latin America, Asia-Pacific, and the Middle East & Africa are the segmentation of global diabetes associated ophthalmic treatment industry. Among all the regions, North America acquired the lion’s share in 2020. The significant share in the region is attributed to the growing number of diabetic patients, the increasing elderly population, the existence of well-established players, and the increasing demand for advanced healthcare facilities. Moreover, the Asia-Pacific diabetes associated ophthalmic treatment market is anticipated to witness the fastest growth rate (CAGR) during the projected years 2021 – 2028. The high growth in the region is credited to the robust increase in diabetes patients, growing eye-related disorders, growing awareness for the treatment of diabetes, and an increase in the number of favorable government initiatives.
Global Diabetes Associated Ophthalmic Treatment Industry Segment Analysis
Market By Type
Market By Application
· Diabetic Retinopathy
· Diabetic Macular Edema
· Diabetic Associated Macular Degeneration
· Eye Allergy and Infection
Market By End-User
· Ambulatory Surgical Centers
· Ophthalmic Clinics
Diabetes Associated Ophthalmic Treatment Market Prominent Players
This section of the report identifies the market's major players. Alcon, Abbott Medical Optics, Allergan, Bayer AG, Bausch Health, Carl Zeiss Meditec, Ellex Medical Lasers Ltd., Genentech, Inc., F. Hoffmann-La Roche Ltd, IRIDEX Corp., Johnson & Johnson Services, Inc., Novartis AG, Lumenis, Pfizer, Inc., Santen Pharmaceutical Co. Ltd., Quantel, and Topcon Corp. are the key companies mentioned in the research.
Diabetes Associated Ophthalmic Treatment Market Regions
· Rest of Europe
· Rest of Latin America
· South Korea
· Rest of Asia-Pacific
Middle East & Africa
· South Africa
· Rest of Middle East & Africa